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Abstract
Background: The amyloid β-peptide is a ubiquitous peptide, which is prone to aggregate forming
soluble toxic oligomers and insoluble less-toxic aggregates. The intrinsic and external/
environmental factors that determine Aβ aggregation in vivo are poorly understood, as well as the
cellular meaning of this process itself. Genetic data as well as cell biological and biochemical
evidence strongly support the hypothesis that Aβ is a major player in the onset and development
of Alzheimer's disease. In addition, it is also known that Aβ is involved in Inclusion Body Myositis,
a common myopathy of the elderly in which the peptide accumulates intracellularly.
Results:  In the present work, we found that intracellular Aβ aggregation in muscle cells of
Caenorhabditis elegans overexpressing Aβ peptide is affected by two single amino acid substitutions,
E22G (Arctic) and V18A (NIC). Both variations show decrease intracellular amyloidogenesis
compared to wild type Aβ. We show that intracellular amyloid aggregation of wild type Aβ is
accelerated by Cu2+ and diminished by copper chelators. Moreover, we demonstrate through
toxicity and behavioral assays that Aβ-transgenic worms display a higher tolerance to Cu2+ toxic
effects and that this resistance may be linked to the formation of amyloid aggregates.
Conclusion: Our data show that intracellular Aβ amyloid aggregates may trap excess of free Cu2+
buffering its cytotoxic effects and that accelerated intracellular Aβ aggregation may be part of a cell
protective mechanism.
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Background
Aberrant protein aggregation is a common feature of late-
onset amyloidogenic diseases, such as Alzheimer's disease
(AD) and Inclusion Body Myositis (IBM) [1]. A peptide of
39–43 mer derived from the amyloid precursor protein
(APP), the amyloid β-peptide (Aβ), is the main constitu-
ent of senile plaques (SPs) in AD [2], and it is also one of
the hallmarks of IBM, a common myopathy characterized
by the presence of intracellular amyloid aggregates in skel-
etal muscle cells [1,3]. IBM patients show progressive
muscle weakness, compromised muscle innervation [4]
and muscle fibre degeneration [5]. Besides the presence of
senile plaque-like inclusions, most molecules known to
be involved in IBM are also present in AD [6].
Dominant mutations in the APP gene are associated with
rare cases of familial AD, in which brain and vascular
amyloid deposits are formed earlier than in sporadic cases
[7]. One type of familial AD is linked to a point mutation
in the Aβ peptide (E22G, Arctic) that accelerates aggrega-
tion of Aβ into protofibrils and fibrils in vitro [8-12]. Some
transgenic mice carrying the Arctic mutation show
increased plaque formation but normal learning and
memory compared to strains carrying the wild type Aβ
[13]. Opposite to the Arctic variant, in vitro studies dem-
onstrated that the NIC mutation (V18A), which is pre-
dicted to favour the α helix conformation over the β sheet
conformation, shows decreased aggregation [14].
Although APP and Aβ have been implicated in several
processes in vitro and in vivo, such as neuronal develop-
ment and cell survival, the in vivo functions of APP and Aβ
remain unclear [7,15,16]. Moreover, the inactivation of
the complete APP gene family has shown that APP is nec-
essary for neurodevelopment and cell adhesion [17]. In
addition, neither the in vivo mechanisms of amyloid for-
mation nor the factors required for this process have been
properly established. It is also unknown if the formation
of insoluble amyloid aggregates is instrumental for the
onset of these amyloidogenic diseases, or if the formation
of amyloid structures is the end product of the cell protec-
tive machinery. SPs are structured as metal-enriched
aggregates that accumulate Cu2+, Fe3+, and Zn2+ [18-20].
In agreement with this, the aggregation state of Aβ-pep-
tide is increased by Cu2+ or Zn2+ [21] and reduced by
metal chelators such as clioquinol [22-24]. However, the
role of copper as deleterious or beneficial in the context of
amyloidogenic diseases is very controversial. For instance,
in a transgenic APP23 mouse model, supplementation of
the diet with bioavailable copper restored normal levels of
SOD-1 activity and decreased the production of soluble
Aβ [25]. From these studies, the structural plasticity of the
SP is becoming evident in agreement with previous struc-
tural data [26]. In light of this evidence we postulate that
the formation of the SP might be triggered by fluctuations
on the levels of transition metals, and could be a part of a
protective homeostatic mechanism gone off-course. How-
ever, it is unknown if these metals are accumulated in the
intracellular amyloid aggregates observed in IBM and if
the aggregation state of Aβ is modulated by transition
metals in this intracellular muscle environment. Interest-
ingly, IBM patients do not develop dementia and AD
patients do not have the muscle weakness characteristic of
IBM, which indicates that these diseases may be triggered
by independent mechanisms [1].
Caenorhabditis elegans has an APP homologue but this pro-
tein lacks a region equivalent to the Aβ-peptide [27].
However, several studies carried out in Aβ overexpressing
C. elegans [6] have established that the formation of amy-
loid deposits [28] could induce oxidative stress [29], stress
response [30,31] and up- or down-regulation of different
genes [32]. However, the toxic Aβ-species responsible for
these effects detected in Aβ-transgenic worms have not
been thoroughly identified, but they are likely to be a spe-
cific type of Aβ oligomers rather than mature Aβ amyloid
aggregates [33-35]. It is important to mention that the
paralysis phenotype is only observed in Aβ expressing C.
elegans in a dominant rol-6 background (strains carrying a
mutation in a collagen gene) [32]. In fact, the great major-
ity of IBM patients show muscle weakness that translates
in a lower quality of life but not paralysis or decreased
longevity [36].
In the present work, we evaluated intrinsic and extrinsic
factors on the aggregation of intracellular Aβ peptides
constitutively overexpressed in muscle cells of C. elegans.
Our results indicate that intracellular Aβ aggregation is
selectively affected by single amino acid substitution,
which is in agreement with previously published in vitro
data [14]. Under our experimental conditions, we find
that the NIC mutation (V18A) did form fewer Thiofla-
vine-S (ThS)-positive aggregates compared to Aβ wt. Nei-
ther non-aggregating Aβ peptide nor aggregating Aβ
peptide induced strong paralysis phenotypes in these ani-
mals in a wild type background. However, Aβ wild type
affected the worms' motility as they aged mimicking the
muscle weakness observed in IBM patients. Therefore, we
asked the question whether CuCl2 could modulate the
aggregation of intracellular Aβ-peptide in muscle cells, as
it is apparent with the extracellular Aβ-peptide in trans-
genic vertebrate models for AD [22,37]. We found that
Cu2+ increases the number of intracellular ThS-positive
aggregates present in this model. In contrast, the presence
of the Cu-chelators histidine and clioquinol in the grow-
ing medium decreases the formation of amyloid deposits.
Surprisingly, the Aβ-expressing animals, in spite of pro-
ducing a great number of amyloid aggregates in the pres-
ence of Cu2+, exhibited increased tolerance to the
cytotoxic effects of CuCl2 compared to control animals.Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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Therefore, the present evidence suggests, for the first time,
that intracellular amyloid deposits are dynamically struc-
tured by the presence of metals in muscle cells, and that
the formation of intracellular Aβ aggregates could be a
part of the homeostatic mechanism responsible for pro-
tecting cells against abrupt changes in Cu2+ levels.
Results
The NIC Aβ1–42 variant displays a low rate formation of 
intracellular amyloid deposits in C. elegans muscle cells
In order to investigate the key intrinsic determinants of
the human Aβ sequence for Aβ intracellular amyloid
aggregation, we constructed transgenic C. elegans strains
that express two different variants, Arctic (E22G) and NIC
(V18A) (Fig. 1A, B, C and 1D), in muscle cells as described
in the Methods section. Interestingly, despite having gen-
erated several transgenic lines that expressed the Arctic
variant, all of them showed levels of expression far lower
than those expressing the wild type or the NIC variant
(Fig. 1C and 1D). One possibility is that the overexpres-
sion of the Arctic variant in C. elegans muscle cells is too
harmful and therefore the only surviving transgenic lines
were those with low Aβ Arctic expression. For our experi-
ments we used the strain NIC2, with Aβ load similar to
that of the Aβ wt expressing strain, and Arctic 6.
We then analyzed the degree of amyloidosis at different
times during the animal's life to establish the pattern of
intracellular aggregation. Fig. 2(A, B) shows the time
course of amyloid formation as visualized by ThS stain-
ing. The animals were processed and stained at 48, 72, 96
and 120 h after being synchronized at the embryo stage.
All transgenic strains show an increment in the total amy-
loid deposit area as they age (Fig. 2B). However, the ani-
mals expressing the Aβ variants show fewer amyloid
aggregates than those that express the Aβwt at all ages. The
worms expressing the NIC variant start showing amyloid
deposits by 48 h but to a lesser extent than those express-
ing the Aβwt. Over the next time points (up to 120 h) the
formation of amyloid deposits increased in these animals,
but to a much lesser extent than in those expressing the
Aβwt (Fig. 2A, B) as anticipated from previous in vitro
experiments [14]. We were not able to detect any ThS pos-
itive spots until 72 h in the animals that express the Arctic
variant, which suggests a delay in the formation of mature
amyloid deposits as expected. However, in the next time
points, the degree of amyloid formation in these trans-
genic animals was very poor, even lower than those
expressing the NIC variant (Fig. 2A, B). We expect this low
level of amyloid formation of the Arctic variant is due to
the poor expression of the transgene compared with the
strains carrying the wild type and NIC variants (Fig. 1C,
D). Fig. 3 shows the expression of the three Aβ variants in
the transgenic C. elegans lines by immunofluorescence
(120 h). They all show expression of the Aβ peptide
(green) in the muscle cells identified by phalloidin stain-
ing of actin filaments (red). As shown in the orthogonal
analyses (Fig. 3B, D, F) the Aβ concentrated in aggregates
is mainly located between the actin filaments, which are
well observed in C. elegans overexpressing the Aβwt vari-
ant (Fig. 3A, B). Even though the Arctic variant formed
very few and small amyloid deposits (probably as a con-
sequence of low expression of the transgene (Fig. 1D)),
the peptide accumulates in what appears to be fairly big
amorphous aggregates, which were Aβ-immunoreactive
(Fig. 3C, D). We do not observe clear muscle degeneration
in any of the transgenic strains since actin fibers look fairly
intact (Fig. 3).
Cu2+ modulates intracellular Aβ amyloidosis in transgenic 
C. elegans
To evaluate if the aggregation state of Aβ expressed in the
muscle cells of the worms could be altered by environ-
mental factors, we decided to expose the worms to copper,
mainly because there is a large body of evidence indicat-
ing that the aggregation of Aβ in the brain can be modu-
lated by transition metals [25,38,39]. We performed
experiments with copper using the strain expressing the
human wild type Aβ peptide, since it is the most com-
monly found in amyloidogenic diseases, the best charac-
terized, and it behaves as expected in our previous studies.
We first analyzed the formation of amyloid aggregates by
staining synchronized populations of animals cultured on
Cu2+, histidine and clioquinol supplemented medium
every 24 h. Time zero was established as the time the eggs
were harvested and seeded onto agar plates supplemented
with the CuCl2, histidine or clioquinol. The CuCl2 con-
centrations used in the experiments were determined by
preliminary studies of viability, fertility and Cu2+ incorpo-
ration in the wild type (N2) strain and analysis of stress
induction in the hsp-16:GFP transgenic strain CL2070
[31,40]. Based on these studies we decided to use a con-
centration of 150 μM CuCl2, because it did not affect the
survival of the worms. Cu-chelators were also used at a
concentration of 150 μM. As previously reported, ThS
reactive deposits were not observed in very young animals
although their presence has been established even in
embryos by staining with the more sensitive Congo-red
derived dye X-34 [41]. We started seeing ThS positive
deposits 48 h after the eggs where seeded on the plates,
when most of the animals were L4 larvae (data not
shown). Before this time, it was not possible to perform a
quantitative analysis between the different treatments.
The number of ThS positive deposits was quantified ante-
rior to the pharyngeal bulb in the cephalic region of the
worms (Fig. 4A), as described in the Methods section. Up
to 72 h of treatment, the differences in the number of
amyloid deposits between the animals exposed to CuCl2,
histidine or clioquinol did not appear significantly differ-
ent from controls (Fig 4C). After 96 h of treatment, theMolecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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Figure 1 (see legend on next page)Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
Page 5 of 17
(page number not for citation purposes)
formation of ThS-positive deposit was more abundant in
the worms grown in CuCl2 than in the worms cultured in
the control medium (Fig 4B a–b, C). At this time, the
worms cultured in the agar supplemented with Cu-chela-
tors developed scarce amyloid deposits, significantly less
than the number of deposits formed in the worms grown
in the control medium (Fig. 4B a–d; C). The same pattern
was observed at 144 h of treatment (Fig. 4C). We con-
firmed this quantification by measuring the total aggre-
gate area in the worm's cephalic region at 96, 120 and 144
h (Fig. 4D). As expected, the CuCl2 treatment increased
the total deposit area, while histidine and clioquinol
reduced it significantly. Moreover, at this time, the few
aggregates formed in the presence of histidine and clio-
quinol seemed to have a more diffuse morphology than
the ThS-amyloid aggregates formed in the presence of
CuCl2 and controls (Fig. 4Bc and 4d). In addition, the
treatment with clioquinol often produced a virtual
absence of discernible aggregates (Fig 4Bd).
Cu2+ tolerance in Aβ- transgenic C. elegans
Aβ has a strong affinity for Cu2+ [42], therefore, we set up
to test whether there was a differential tolerance to the
toxic effects of CuCl2 between the Aβ expressing worms
(CL2120) and the controls (CL2122). We reasoned that if
Cu2+ becomes bound to Aβ, there would be less free Cu2+
to cause cell damage. To test this hypothesis we performed
toxicity assays in which we exposed 96 h old Aβ-express-
ing worms and their controls to a range of copper concen-
trations ranging from zero (no copper added to the
medium) to 450 μM in liquid medium during 24 h. In
this way we were able to define survival curves for both
populations and found a significant shift to the right for
the Aβ transgenic animals (Fig. 5A). The lethal concentra-
tion at which half of the population dies (LC50) was sig-
nificantly higher for the animals expressing the Aβ peptide
(366 ± 2 μM) than the controls (268 ± 8 μM). These
results show that the Aβ transgenic worms are more resist-
ant than controls to high Cu2+ concentrations suggesting
that there might be less metal available to produce cell
damage in this strain. We confirmed that the animals
exposed to high concentrations of CuCl2 (150 μM) during
96 and 120 h incorporated more Cu2+ (≈10 μg/g) than the
animals grown on regular medium (≈ 0.1 μg/g) (Table 1).
Moreover, Cu2+ supplementation did not induce changes
in Zn2+, Fe3+, Mn2+ or Al3+ levels (data not shown). We did
not observe any significant difference in constitutive Cu
(or Zn2+, Fe3+, Mn2+ and Al3+) levels between the Aβ-trans-
genic  C. elegans and their controls, indicating that the
presence of Aβ does not affect Cu2+ absorption from the
agar medium. Therefore, the aggregation of intracellular
Aβ was mediated by direct reaction with elevated Cu2+. In
fact, the Aβ-transgenic animals and their control counter-
parts exposed to CuCl2, incorporated about 100 times
more Cu2+ than the animals grown under normal culture
conditions. However, we did not observe any statistically
significant difference in the amount of incorporated Cu2+
between the Aβ-transgenic C. elegans and their controls
under either condition (no CuCl2 added and CuCl2 sup-
plementation) (Table 1), indicating that the presence of
Aβ is not affecting Cu2+ transport, and suggesting that the
effect observed on the experiments could be explained
principally by the interaction between Cu2+ and the Aβ
present in the muscle cells of the nematode. These results
show that the Aβ transgenic worms are more resistant
than controls to high Cu2+ concentrations.
In order to confirm that the protective effect of Aβ expres-
sion is limited to copper toxicity we performed CdCl2 and
ZnCl2 toxicity assays. Both metals are known to be toxic
and to elicit a stress response in C. elegans [43-45]. Fur-
thermore, zinc is known to be involved in the metallobi-
ology of Alzheimer's disease [46]. We found that the
survival curves (Fig. 5C, D) are almost identical between
Aβ expressing worms and controls in both cases. The dif-
ferences in LC50 for cadmium (CL2120: 1.55 ± 0.02 mM;
CL2122: 1.59 ± 0.03 mM) and zinc (CL2120: 4.9 ± 0.8
mM; CL2122: 4.8 ± 0.4 mM) are not statistically signifi-
cant between the strains. These results exclude the possi-
bility that Aβ overexpression may be providing a more
general protective effect, at least to metal toxicity.
Finally, to correlate amyloid aggregate load with resist-
ance to copper toxicity, we performed lifespan experi-
Transgenic C. elegans strains express the Aβ wild type and its variants Arctic and NIC Figure 1 (see previous page)
Transgenic C. elegans strains express the Aβ wild type and its variants Arctic and NIC. A. Amino acidic sequences 
of the Aβ1–42 peptide (wild type) and its variants Arctic and NIC expressed in the transgenic C. elegans strains used in this 
study. B. PCR results show the presence of the DNAs that encode the different peptides in the transgenic strains. CL2120 is 
the strain that express Aβ wt and CL2122 is the control strain that do not express the peptide. NIC corresponds to transgenic 
line NIC2 and Arctic corresponds to transgenic line Arctic 6. unc-119 is the strain used to construct the transgenic lines carry-
ing the NIC and Arctic variants. C. Western blot analysis using the anti-Aβ antibody 6E10 showing the expression of Aβ in the 
CL2120 (wild type Aβ) strain and in two NIC transgenic lines (NIC 1 and NIC 2). The lane marked as "no Aβ " correspond to 
strain CL2122. D. Western blot analysis using the same antibody as in C showing the expression of Aβ in strain CL2120 (wild 
type Aβ) and in four Arctic transgenic lines (Arctic 13, Arctic 6, Arctic 37, Arctic 5D). The lane marked as "no Aβ " corre-
spond to strain CL2122. α-Tubulin was used as loading control in C and D.Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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Amyloid formation in transgenic C. elegans expressing different Aβ variants Figure 2
Amyloid formation in transgenic C. elegans expressing different Aβ variants. A. Images show ThS stained C. elegans 
that express the Aβ1–42 wt or its variants Arctic and NIC. The visualization of the amyloid deposits (arrow heads) in these 
strains is shown at 48 h (larval stage L4), 72 h (1 day old adult), 96 h (2 day old adult) and 120 h (3 day old adult) of develop-
ment. The images are representative of 4 experiments where 40 worms were analyzed for each time point. Bar 20 μm. B. 
Quantification of amyloid deposit area in ThS stained transgenic C. elegans expressing the Aβ variants mentioned above. The 
quantification of the amyloid deposit area was also done at 48, 72, 96 and 120 h of development in the head of at least 40 
worms for each time point, from the tip of the heat to the end of the pharynx (see Fig. 4A).Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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Transgenic C. elegans strain expressing the Arctic Aβ peptide shows high levels of non-amyloidogenic aggregates Figure 3
Transgenic C. elegans strain expressing the Arctic Aβ peptide shows high levels of non-amyloidogenic aggre-
gates. Panels A, C and E show confocal images of 120 h old worms that express the Aβwt, the Arctic and the NIC variants, 
respectively, stained with anti-Aβ antibodies (green) and phaloidin (red) to show the actin filaments in body wall muscle cells. 
Panels B (Aβwt), D (Aβ Arctic) and F (Aβ NIC) show the orthogonal view of the same animals shown in A, C and E, to estab-
lish the location of the Aβ aggregates in relation to the actin filaments. Bar 20 μm.Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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Figure 4 (see legend on next page)Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
Page 9 of 17
(page number not for citation purposes)
ments to determine if Aβ expressing worms show longer
lifespan than controls under 150 μM copper. We found
that Aβ worms show a small but significant increase in
median and total lifespan (Fig. 5B) demonstrating the
protective effect of Aβ when the worms were chronically
exposed to copper. When cultured on regular agar, the Aβ
expressing worms and the control animals show a similar
lifespan (Additional file 1).
Aβ- transgenic C. elegans are protected from Cu2+ toxicity 
in behavioral assays
To further corroborate the protective effect of Aβ expres-
sion to copper toxicity we performed thrashing assays
[47]. These assays measure motor deficits in liquid
medium and have been used extensively in studies of
mutants that affect the function and/or structure of the C.
elegans neuromuscular junction [47-49]. We first evalu-
ated the motility of Aβ expressing worms and controls
that had been cultured in regular agar plates for 72 and
120 h (from the embryo stage). We found that the trans-
genic Aβ animals move 40% slower than controls (Fig. 6),
indicating that Aβ is indeed affecting the worms' behav-
iour, even though this is not evident when they crawl on
agar plates. Then, we evaluated the motility of Aβ express-
ing animals and their controls after being cultured on agar
medium supplemented with 150 μM CuCl2 during the
same periods of time (72 and 168 h). We found that while
the control animals show decreased movement at both
time points after being cultured in copper rich agar plates,
the Aβ expressing worms are not affected under the same
conditions and they even show significant improvement
(Fig. 6 and Additional files 2 and 3).
Discussion
Most of the studies performed to understand intracellular
Aβ aggregation and amyloid formation have been done
using in vitro systems. Therefore, neither the in vivo mech-
anisms of amyloid formation nor the factors required for
this process have been established [15]. In the present
work, we evaluated intrinsic and extrinsic factors in the
aggregation of Aβ peptides constitutively overexpressed in
muscle cells of Caenorhabditis elegans. Under our experi-
mental conditions, we found that Aβ peptide carrying the
Arctic (E22G) or the NIC mutation (V18A) did form few
ThS-positive aggregates compared to Aβwt. The results
obtained with the NIC (V18A) variant are in agreement
with previously published in vitro data [14]. This mutation
is expected to favor the α helix over the β sheet conforma-
tion, which would cause a decrease in amyloidosis [14].
However, the results obtained with the Arctic mutation
(E22G) are at variance with the literature [50]. The initial
delay in the formation of aggregates is in agreement with
the kinetics of aggregation of the Arctic variant in vitro in
which there is a lag in the formation of amyloid in favor
of the development of protofibrils, when compared with
Cu2+ and Cu-chelators modulate the aggregation state of intracellular Aβwt in transgenic C. elegans Figure 4 (see previous page)
Cu2+ and Cu-chelators modulate the aggregation state of intracellular Aβwt in transgenic C. elegans. A. The 
white rectangle on the DIC image of a C. elegans hermaphrodite (top picture) indicates the region of the worm where all quan-
tifications were done (the same region, stained with ThS in seen below). * Indicates the position of the pharyngeal bulb. B. 
Morphology of ThS-positive amyloid deposits formed in the presence of Cu2+ and Cu-chelators. Images correspond to C. ele-
gans grown on regular NGM agar plates (a), treated with 150 μM CuCl2 (b), 150 μM histidine (c) or 150 μM clioquinol (d) for 
144 h. The amyloid deposits were stained with ThS and photographed under an epifluorescence microscope. Arrows indicate 
ThS positive amyloid aggregates. The images are representative of 4 experiments where 40 worms were analyzed for each 
treatment. Bar 20 μm. C. The graph represents the number of aggregates formed anterior to the pharyngeal bulb at different 
times (48–144 h) under control conditions (white bars) and when the animals were treated with CuCl2 (150 μM, black bars), 
histidine (150 μM, dark grey bars), or clioquinol (150 μM, pale gray bars). Bars indicate standard error, **p < 0.01; ***p < 
0.001. D. The graph shows the digital quantification (Sigma Scan Pro 5) of the ThS-positive amyloid deposits present anterior 
to the pharyngeal bulb. The graph represents the total area of aggregates formed anterior to the pharyngeal bulb at different 
times (96–144 h) under control conditions (white bars) and when the animals were cultured in the presence of CuCl2 (150 μM, 
black bars), histidine (150 μM, dark grey bars), or clioquinol (150 μM, pale gray bars). Bars indicate standard error, *p < 0.05; 
**p < 0.01; ***p < 0.001. The p values indicate differences between a given treatment and the control..
Table 1: Copper incorporation into Aβ expressing C. elegans and 
controls
Age [h] Strain Cu2+ Content
[μg/g protein]
No copper added CuCl2 150 μM
96 No Aβ 0.350 ± 0.458 8.831± 1.077
Aβ1–42 0.169 ± 0.142 12.109 ± 2.523
120 No Aβ 0.128 ± 0.110 9.931 ± 0.930
Aβ1–42 0.068 ± 0.015 9.224 ± 1.989
Quantification of Cu2+ incorporated in control (CL2122 = no Aβ 
expression) and Aβ-transgenic (CL2120 = Aβ1–42) C. elegans. Worms 
were grown in the presence of CuCl2 (150 μM) or under control 
conditions (no copper added) for 96 and 120 h. The Cu2+ content 
(μg/g) was determined by ICP-MS. Data are means ± S.E.Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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the Aβwt [12]. However, the poor amyloidogenesis in
later time points (even lower than the NIC variant) is
probably due to low transgene expression since the Arctic
variant is known to be highly amyloidogenic as estab-
lished in studies of transgenic mice expressing this human
variant in the nervous system [13,50]. Our inability to
produce transgenic lines that constitutively express high
levels of Aβ Arctic could be related to the deleterious effect
of high levels of this variant during embryonic stages that
may have preclude us from obtaining such strains. On the
other hand, the immunofluorescence experiments show
that much of the Aβ Arctic is aggregated in what appears
C. elegans that express Aβ are resistant to Cu2+ toxicity Figure 5
C. elegans that express Aβ are resistant to Cu2+ toxicity. A. Control (open circles) and Aβ wt expressing animals (black 
circles) were exposed to a range of CuCl2 (A), CdCl2 (C), and ZnCl2 (D) concentrations in liquid K medium for 24 h. The 
number of worms that remained alive was determined under a stereoscope by visual inspection. The experiments were per-
formed in triplicate. Data are means ± S.E. **p < 0.01; ***p < 0.001. B. Survival curves of control worms and Aβ worms cul-
tured on 150 μM CuCl2. Comparison of survival curves using the Log-rank (Mantel-Cox) test yielded a p value of 0.0066 (n = 
138).Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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to be amorphous deposits. Perhaps, there are muscle
expressed factors that prevent the formation of mature
amyloid deposits of the Aβ Arctic variant.
In our model, Aβwt peptide expression induced a clear
decrease in the worms' motility (Fig. 6), which could be
compared to the progressive muscle weakness present in
IBM patients. The lack of muscle degeneration observed in
the Aβwt expressing animals suggests that the Aβ peptide
might not be sufficient to induce a stronger myopathy by
itself in the muscle cells of worms, and that extra factors
might be needed to fully replicate IBM symptoms in C.
elegans. The situation could be very similar to that seen in
triple transgenic mice models for AD, where mice need to
overexpress Aβ together with Tau and presenilin (all
mutant variants) to replicate the brain human features
characteristic of the pathology [51]. Therefore, Aβ appar-
ently needs to act with other factor/s present in the muscle
to fully induce IBM symptoms in worm muscle [1].
We also showed that Cu2+ and the Cu2+ chelators histidine
and clioquinol can modulate the formation of intracellu-
lar amyloid aggregates in C. elegans muscle cells. Copper
ionophores like clioquinol and PBT2 show benefits in
transgenic mouse models and phase 2 clinical trials of AD
[22,24,52]. Despite the differences in cellular location,
intracellular Aβ aggregation in C. elegans seems to be
enhanced by Cu2+ and diminished by histidine and clio-
quinol in accordance with previous in vitro and in vivo
reports [22,23]. The increased amyloidosis could also be
Aβ-transgenic C. elegans are protected from Cu2+ toxicity in motility assays Figure 6
Aβ-transgenic C. elegans are protected from Cu2+ toxicity in motility assays. The graph represents the results of the 
thrashing assays (movement in liquid medium) performed on control and Aβ expressing worms after being cultured on regular 
agar or in copper supplemented agar for 72 or 168 h stating at the embryo stage. Statistical analysis: t-test to compare control 
worms (grey bars) with Aβ expressing worms (white bars) cultured on regular agar plates (no Cu2+) during 72 and 168 h. *** p 
< 0.001. t-test to compare control worms cultured on copper supplemented agar with control worms cultured on regular agar 
during 72 and 168 h. # p < 0.005, ### p < 0.001; and to compare Aβ worms cultured on copper supplemented agar (150 μM) 
with Aβ worms cultured on regular agar during 72 and 168 h. # p < 0.005, ### p < 0.001. Bars indicate standard error. See 
representative videos in Additional files 2 and 3.Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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the result of higher Aβ expression brought about by Cu
exposure and lower Aβ expression caused by Cu-chelator
treatment. This situation is not likely to be the case
because the constitutive unc-54 promoter is driving Aβ
expression. Moreover, it has been shown that in addition
to aggregated Aβ-peptide there is an important pool of
soluble peptide in worms expressing Aβ [30]. Therefore,
increased peptide synthesis is not necessary for an even-
tual increment in Aβ for interaction and subsequent
aggregation in the presence of Cu2+. We did, however,
evaluate Aβ expression in worms subjected to the different
treatments by semi-quantitative RT-PCR and found that
there were no significant differences in its expression
(data not shown). Therefore, these results support a piv-
otal role of Cu2+ in the aggregation state of intracellular
Aβ.
In the present study, the animals were treated continu-
ously with CuCl2, histidine or clioquinol since they were
embryos; at this stage there is no Aβ aggregation that can
be observed by ThS staining although some aggregates
have been detected with the X-34 dye [41]. Therefore, we
have yet to establish whether treating animals with histi-
dine or clioquinol later in life, once a significant number
of deposits have been formed, can eliminate or reduce the
number and/or size of the aggregates. Although we have
shown an effect of Cu2+, histidine and clioquinol on the
formation of intracellular amyloid deposits in muscle
cells by histochemical staining with ThS, we have not yet
resolved the question of the relative concentrations of sol-
uble versus insoluble aggregated Aβ and their changes
upon treatment with Cu-chelators. It would be very
informative to clarify this point by double staining with
ThS or X-34 to visualize the deposits, and Aβ antibodies
that recognize both soluble and insoluble forms of the
amyloid peptide. This experiment would clarify whether
Cu2+ and Cu-chelators influence the equilibrium between
both Aβ forms.
The differences observed among individuals exposed to
the same treatments could be due to the developmental
stage at which the animals start their exposure to the dif-
ferent agents. Even though we start the treatments on
embryos, there is some difference in the actual develop-
mental stage of the embryo (data not shown). Although
this is a possibility, we do not think it is the case, since we
have observed similar differences in animals cultured on
standard medium. It is unlikely that the differences
observed between same age individuals are due to genetic
background. Self-fertilizing reproduction in C. elegans pre-
cludes much genetic variation in the strains. The strains
used in our studies are transgenic strains in which several
copies of Aβ had been integrated into the genome. How-
ever, integration of a transgene into the genome does not
always prevent mosaicism and/or differences in expres-
sion between individuals [53].
Another caveat is that we do not know if there is enrich-
ment of metals (Cu, Zn and others) in the intracellular
amyloid deposits of C. elegans muscle cells as is the case in
the extracellular amyloid aggregates found in AD affected
neuronal tissue [20]. The determination of metal levels in
the muscle aggregates would be an important step in
drawing a firmer analogy between AD extracellular brain
aggregates and intracellular muscle deposits.
Perhaps the most striking finding is that the Aβ-expressing
animals, in spite of producing great number of amyloid
aggregates in the presence of Cu2+, exhibited increased tol-
erance to the cytotoxic effects of CuCl2 compared to con-
trol animals and suggests that there might be less metal
available to produce cell damage in this strain. The results
from the behavioural experiments together with the
results obtained in the toxicity assays offer strong evidence
that Aβ may be providing protection to Cu2+ toxicity.
Interestingly, the Aβ expressing worms that were exposed
to CuCl2 move better than those that were not cultured in
the presence of this transition metal, suggesting that per-
haps the increase in amyloid deposits in these treated
worms is limiting the amount of the more toxic oligo-
meric species [33-35]. Our findings connect with those of
other authors showing that increased Aβ deposition asso-
ciates with decrease levels of neuronal oxidative damage
in Down Syndrome and AD [54-57]. It has also been sug-
gested that the chelation of redox-active copper and iron
may be the most important mechanism by which Aβ
exerts its protective function [58], and that at moderate
copper concentrations, Aβ acts as an antioxidant to pre-
vent Cu2+ catalyzed oxidation of biomolecules [59]. The
levels of intracellular copper must be strictly regulated to
prevent aberrant reactive oxygen species generation result-
ing in neuronal and muscle damage. In fact, intracellular
free copper has been estimated to be almost nil [60], and
is under the control of a robust metalloprotein array that
rapidly and efficiently buffers free copper bioavailability.
However, this protein array is clearly altered in age-related
diseases such as Alzheimer's disease [61], which may
explain why copper is accumulated in amyloid plaques of
people suffering of this disease [20]. Moreover, a more
recent report described that total brain copper levels
increase in aged mouse [62]. Considering that age is a risk
factor for AD neuropathology, brain copper rise in elderly
humans may be one of the neurochemical factors relevant
in the onset of AD. Moreover, cellular acidosis could facil-
itate the release of copper from metal binding proteins
[63]. Interestingly, brain acidosis is observed in AD [64],
which may facilitate the release of copper from copper-
binding proteins increasing the formation of Aβ-Cu aggre-Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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gates. This may be also part of the mechanism that
increases copper bioavailability in IBM.
Therefore, the present evidence suggests that intracellular
amyloid deposits are dynamically structured by metals,
and that Aβ may be a component of the system that spe-
cifically controls copper homeostasis at the cellular level
[65-67].
Much research has been done on the possible role of cop-
per and other metals such as zinc and iron on the devel-
opment of AD, but so far no consensus has been reached
in terms of the specific involvement of copper in this
pathology, and conflicting reports point either to a delete-
rious role of copper [68] or a beneficial one [25]. Moreo-
ver, there is practically no data available about the
possible role of metal homeostasis on other disorders
characterized by amyloidosis such as sporadic IBM.
Conclusion
In this study we show in a C. elegans model that the intra-
cellular senile plaque-like structures formed in muscle
cells and characteristic of IBM can be modulated by cop-
per and copper chelators. The accelerated Aβ aggregation
in the presence of copper seems to be linked to a higher
tolerance to the cytotoxic effects of this metal. Our results
suggest that the formation of intracellular Aβ aggregates
could be part of a mechanism that defends the cell against
sudden changes in copper concentration.
Methods
Solutions
Distilled H2O (dH2O) used in buffer preparations was
submitted to resin treatment in order to eliminate organic
compounds, cations and anions. After treatment, the
resultant dH2O had a resistance value of 18 MΩ/cm.
Nematode propagation and strains
Transgenic strains CL2120 and CL2122 were a gift of Dr.
Christopher Link and were described earlier [28]. Briefly,
CL2120 expresses the Aβ1–42 peptide under the control
of the unc-54 (myosin heavy chain) promoter that drives
expression to the body wall muscle cells. These animals
form intracellular amyloid deposits constitutively in their
muscle cells [69]. CL2122 has the same vector as CL2120,
minus Aβ1–42, incorporated into the genome and there-
fore it does not form amyloid aggregates. Both strains
have mtl-2/GFP as marker gene and therefore they express
GFP in the intestinal cells. The worms were cultured on
regular 35, 60 or 100 mm culture plates with NGM agar
seeded with the bacterial strain OP50 [70]. The agar and
the bacterial cultures were supplemented with histidine
(Sigma), clioquinol (Sigma) and CuCl2 (Sigma) at a con-
centration of 150 μM. All strains were maintained at
20°C. Worm cultures were synchronized by the
hypochlorite method [71] and the resulting eggs were
seeded onto the previously described agar plates. The ani-
mals were collected every 24 h by washing the plates with
M9 buffer [71]. The worms were precipitated in a clinical
centrifuge and the M9 removed. The nematodes were then
stained as described below.
Aβ mutagenesis
Construction of the transgenic strains expressing the Aβ
variants, Arctic (E22G) and NIC (V18A) (Fig. 1A), were
obtained by site directed mutagenesis on the pCL12 plas-
mid (kindly provided by Dr. Christopher Link) that car-
ries the human wt Aβ1–42 peptide (with a signal peptide
in the N-terminus) under the control of the unc-54 pro-
moter that drives expression to the body wall muscle cells
[28]. The NIC mutation (V18A) induces a significant
increment in the α-helical content of Aβ and dramatically
diminishes fibrillogenesis in vitro [14]. The primers used
to generate the Arctic (5'TGGTGTTCTTTGCAGGAGATGT
GGGTTCAAA3' and its complementary anti-sense primer)
and NIC (5'ATCATCAAAAATTGGCGTTCTTTGCAGAAGA
3' and its complementary anti-sense primer) mutations
were obtained commercially (Invitrogen). We obtained
plasmids pPG110 and pPG120 carrying the Arctic and the
NIC variant respectively as established by sequencing the
DNA inserts. The transgenic lines were created using
microparticle bombardment of the plasmid of interest
and the selectable co-transformation marker unc-119
(pJN254) into unc-119 (e2498) mutants, as described ear-
lier except that we used tungsten particles instead of gold
particles [72]. The presence of each transgene was deter-
mined by PCR (primer sense 5'TGACCGTGGAAGATTA 3'
located in the unc-54  promoter and primer antisense
5'GTCCAATGATTGCACCT 3' between bases 1208 and
1224 of the pCL12 plasmid and its derivatives pPG110
and pPG120 (Fig. 1B). The expression of the transgenes
was established by western blot analysis (Fig. 1C and 1D)
and immunofluorescence (6E10 antibody, Sigma) (Fig.
3). We obtained 4 transgenic lines that express the NIC
variant and 10 expressing the Arctic variant. For Western
analysis we choose lines in which the transgene was incor-
porated into the genome and therefore transferred to
100% of the progeny. For the analysis of intracellular
aggregation (ThS and immunofluorescence) we choose
lines with equivalent Aβ expression (NIC2). This was not
possible for the Arctic variant since it we could not obtain
strains expressing this variant at high levels, but we never-
theless analysed strain Arctic 6.
Western blot analysis
Worms were collected form the plates with M9 buffer,
transferred to tubes, centrifuged and washed two times to
eliminate bacteria. The final worm pellet was resuspended
in 100 μl lysis buffer (50 mM HEPES pH = 7.5; 6 mM
MgCl2; 1 mM EDTA; 75 mM sucrose; 25 mM benzami-Molecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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dine; 1 mM DTT; 1% Triton X-100) and frozen at 80°C.
The samples were sonicated 2 times on ice for 15 seconds
and centrifuged 5 minutes at 10,000 rpm to eliminate the
cuticles. The supernatant was transferred to a new tube
and total protein content was quantified. Then, a volume
corresponding to 50 μg protein was precipitated with ace-
tone. The pellet was resuspended in loading buffer (50
mM Tris-HCl pH6.8; 100 mM DTT; 5% SDS; 10 % glyc-
erol; bromophenol blue; 5% β-mercaptoethanol) and
boiled for 3 minutes (adapted from Wu et al. 2006). The
samples were subjected to electrophoresis on Tris-Tricine
polyacrilamide gels at constant voltage (100 V) at 4°C.
The proteins were then transferred to PVDF membranes
for 2 hours at 4°C (300 mA). The membranes were boiled
in PBS for 3 minutes before blocking with a solution of
PBT plus 5% milk for one hour at room temperature. We
used the anti-Aβ monoclonal antibody 6E10 (Chemicon)
at 1:1,000 dilution or anti-α-tubulin monoclonal anti-
body (Sigma) at 1:5,000 dilution overnight at 4°C. We
used goat anti-mouse HRP as secondary antibody. The
densitometry analysis was performed with Matrix soft-
ware.
Immunofluorescence
We used the monoclonal anti-Aβ antibody 6E10 (Sigma)
and as secondary antibody an anti-mouse Alexa Fluor 488
(Molecular Probes) pre-adsorbed with fixed worms. The
fixation, permeabilization, and staining of the specimens
were performed as described before [73]. Some samples
were also stained with rhodamine-phalloidin (1:4,000)
for the visualization of actin filaments in muscle cells.
ThS fluorescence staining
ThS staining was performed as described before [28] with
the modification that it was done in whole C. elegans pop-
ulations instead of on individual worms. Briefly, the
worms washed from the plates were submitted to a brief
centrifugation at 3,000 rpm in microfuge tubes and fixed
by adding 1 ml 4% paraformaldehyde in PBS pH 7.4 for
24 h at 4°C. The next day, the fixative was removed,
replaced by 0.5 ml permeabilization solution (1% Triton
X-100, 5% β-mercaptoethanol, 125 mM Tris, pH 7.4), and
incubated at 37°C for 24 h. After removing the permeabi-
lization solution the animals were washed in PBS-T (Tri-
ton X-100 0.1%) pH 7.4, stained in 0.125% ThS in 50%
ethanol for 2 min and distained for another 2 min in 50%
ethanol. The 50% ethanol was removed; the worm pellet
was resuspended in a drop of PBS and a small aliquot
observed under a Zeiss Axioplan microscope. If the back-
ground of the staining was too high a second wash with
50% ethanol was performed. The animals were finally
mounted on a drop of mounting medium (DAKO), cov-
ered with a cover slip and sealed. The samples were coded,
and the counting and analysis was performed double
blind. The samples were then observed and photographed
with a Zeiss Axioplan microscope equipped with epifluo-
rescence or analysed in a Zeiss LSM 2000 MT confocal
microscope. To quantify the amyloid aggregates, the ThS
stained deposits present anterior to the pharyngeal bulb
were counted in a minimum of 40 worms in three inde-
pendent experiments.
Image quantification and statistical analysis
Digital quantification of areas positive for ThS fluores-
cence were measured with the Sigma Scan Pro 5 or ImageJ.
The analysis revealed the total average area of the deposits.
The total area of deposits was divided by the total head
area to standardize it to the worm size. Data from the
image analysis microscopy were exported to a Sigma Plot
file or GraphPad Prism 4 for statistical analysis. Results
were expressed as mean ± standard error. Statistical signif-
icance was determined by one-way analysis of variance
(ANOVA); p < 0.05 was regarded as statistically signifi-
cant.
Metal Quantification
C. elegans worms were grown during 96 or 120 h on regu-
lar agar plates or agar plates supplemented with 150 μM
CuCl2. The animals were washed off the plates with
dH2O, placed on microfuge tubes and subjected to three
washes with dH2O, they were then heated 2 times at
100°C for 15 min. All samples were stored at 4°C. To
avoid possible metal contaminations, the tubes used to
collect the samples were previously treated with 0.5%
HNO3 for 24 h, washed with dH2O 3 times and let dry at
20°C. The samples were digested in 200 μl of 12N HNO3
(BDH, ARISTAR) overnight, the next day 200 μl of 1%
HNO3 were added. Samples were further diluted (1:10) in
1% HNO3 for analysis by inductive coupled plasma mass
spectrometry (ICP-MS). ICP-MS was performed using an
UltraMass 700 (Varian Inc., Australia). Tissue samples
were prepared in triplicate for all treatments and Cu2+ val-
ues for each sample was determined in triplicate. Cu2+ val-
ues are mean μg/g weight of each C. elegans sample.
Cu2+ toxicity assays
Age-synchronous C. elegans populations were prepared by
transferring eggs to a freshly seeded NGM plate. After 96
h, the worms were transferred to K medium (53 mM
NaCl, 32 mM KCl) supplemented with different concen-
trations of CuCl2 (up to 450 μM) on 24 well microtiter
plates (15–20 worms/well) for 24 h at 20°C [44]. The
number of dead worms was determined by the absence of
touch-provoked movement when prodded with a plati-
num wire. Each independent experiment of a total of
three was performed in triplicate.
Lifespan assays
Lifespan analysis was conducted at 20°C as described pre-
viously [74]. For the lifespan assays, 5–10 adult animalsMolecular Neurodegeneration 2009, 4:2 http://www.molecularneurodegeneration.com/content/4/1/2
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were allowed to lay eggs overnight on regular NGM plates
seeded with OP50 bacteria. Parents were removed the
next day and eggs were allowed to develop at 20°C. L4 lar-
vae were transferred to new regular NGM plates or to 150
μM CuCl2 supplemented plates. This time point was used
as day 0 to account for differences in developmental time
between strains. The worms were transferred to new plates
every day during the first 4–5 days to avoid the mixing of
generations. The number of dead individuals was verified
every two days. A worm was considered dead when it did
not respond when prodded two times with a platinum
wire pick. Worms that died with larvae inside (eggs
hatched before being laid) or those in which the intestine
extruded from the vulva were removed from the sample.
Lifespan curves were generated and analyzed with Graph-
Pad PRISM® version 5.0. Log-rank (Mantel-Cox) test was
used for statistical analysis of survival curves.
Thrashing assays
Individual animals of the same age were placed on an 80
μl drop of M9 buffer. After a 2-minute recovery period the
worms were recorded for 1.5 minutes and the thrashes
counted. A thrash is defined as a change in the direction
of bending at the mid body [47]. For the copper treatment
experiments, the worms to be assayed were exposed to
copper from the embryo (egg) stage in agar plates until
the thrashing experiments were performed at 72 h (1 day-
old adults), and 168 h later (5 day-old adults).
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